GlassScriptPhysician profile
Michael Mercandetti
NPI 1669471959
$1,890.61
in general payments reported to CMS, 2019-2025
16 companies · $46.14 in 2025
The $46.14 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $57.59 · 2021: $96.25 · 2022: $184 · 2023: $1,072 · 2024: $224 · 2025: $46.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $353.17 | 2019-2023 | Puraply |
| Kerecis Limited | $296.73 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Abbvie INC. | $291.51 | 2023-2025 | |
| Horizon Therapeutics Plc | $251.41 | 2020-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $165.49 | 2023-2024 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $147.02 | 2023 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $121.92 | 2023 | Miebo |
| Merz North America, INC. | $82.29 | 2021-2024 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $32.29 | 2023 | Eylea Hd |
| Convatec INC. | $30.60 | 2025 | |
| Astellas Pharma US INC | $25.65 | 2023 | |
| Biotissue Holdings INC. | $23.02 | 2022 | |
| Alcon Vision LLC | $21.97 | 2023 | Eysuvis |
| Mallinckrodt Hospital Products INC. | $17.17 | 2023 | Acthar |
| Vertical Pharmaceuticals, LLC | $15.99 | 2024 | Dsuvia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $14.38 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mercandetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.